Session » SLE – Treatment Poster I

Date: Saturday, November 12, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 0371

A Phase 2, Double-blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101/Lenabasum in Systemic Lupus Erythematosus, an Autoimmunity Centers of Excellence Study (ALE09)

1:00PM-3:00PM: Abstract Number: 0345

Association Between Cumulated Hydroxychloroquine in Systemic Lupus Erythematosus and Development of Cardiac Conduction Alterations: A Multiple Logistic Regression Analysis

1:00PM-3:00PM: Abstract Number: 0359

Attainment of Remission with Anifrolumab: A Post Hoc Analysis of Pooled TULIP-1 and TULIP-2 Datasets

1:00PM-3:00PM: Abstract Number: 0363

Centrally-Acting Angiotensin Converting Enzyme Inhibitor (cACEi) and Angiotensin Receptor Blocker (cARB) Use and Cognitive Dysfunction in Patients with Systemic Lupus

1:00PM-3:00PM: Abstract Number: 0354

Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients by Cumulative Corticosteroid Dose over 1 Year: Real-World Observation of Commercially Insured Adults in the United States

1:00PM-3:00PM: Abstract Number: 0367

Comparative Risk of COVID-19 Among Patients with Systemic Lupus Erythematosus According to Immunosuppressant Use

1:00PM-3:00PM: Abstract Number: 0349

Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in Patients with Non-Renal Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 0356

Early Reductions in Proteinuria with Voclosporin Treatment Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials

1:00PM-3:00PM: Abstract Number: 0364

Efficacy of BIIB059 on Joint and Skin Manifestations in Participants with Systemic Lupus Erythematosus (SLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part A)

1:00PM-3:00PM: Abstract Number: 0361

Gene Expression Pathways Modulated by Anifrolumab in Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 0365

Improvements in Skin Manifestations with BIIB059 Measured by CLASI in Participants with Cutaneous Lupus Erythematosus (CLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part B)

1:00PM-3:00PM: Abstract Number: 0346

Improving Eye Screening Compliance in Patients Taking Hydroxychloroquine in a Community Hospital Setting

1:00PM-3:00PM: Abstract Number: 0358

Long-term Safety and Efficacy of Voclosporin in Hispanic and Latino Patients with Lupus Nephritis

1:00PM-3:00PM: Abstract Number: 0355

Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study

1:00PM-3:00PM: Abstract Number: 0360

Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 0366

Phase II Trial of Enpatoran in Patients Hospitalized with COVID-19 Pneumonia

1:00PM-3:00PM: Abstract Number: 0370

Preliminary Findings from a Randomized Clinical Trial Show a Remotely Delivered Psychological Intervention May Be Beneficial to Youth with Childhood-Onset Lupus

1:00PM-3:00PM: Abstract Number: 0347

Real-World Effectiveness of Belimumab in Patients with SLE in the United States

1:00PM-3:00PM: Abstract Number: 0343

Severe Non-adherence to Hydroxychloroquine Is Associated with Flares, Early Damage, and Mortality in Systemic Lupus Erythematosus: Data from 660 Patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

1:00PM-3:00PM: Abstract Number: 0348

Significant Improvement in Cutaneous Lupus Erythematosus with or Without Systemic Lupus Erythematosus with Belimumab Use – a Systematic Review and Meta-Analysis

1:00PM-3:00PM: Abstract Number: 0350

Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 0353

Steroid-Induced Diabetes in Lupus Nephritis Patients: Classic Risk Factors or a Different Type of Diabetes?

1:00PM-3:00PM: Abstract Number: 0352

The Effect of Belimumab (BEL) on Kidney Outcomes in SLE: Results of a Large Integrated Analysis

1:00PM-3:00PM: Abstract Number: 0351

The Effect of Belimumab to Achieve Low Disease Activity or Remission Based on SLE-DAS in Systemic Lupus Erythematosus: A Single-center Retrospective Study

1:00PM-3:00PM: Abstract Number: 0369

The Longitudinal Measurement Properties and Clinical Application of the PROMIS Fatigue 13a and 10a in Lupus

1:00PM-3:00PM: Abstract Number: 0362

The Renal Activity Index for Lupus (RAIL) Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Renal Responses in Lupus Nephritis

1:00PM-3:00PM: Abstract Number: 0344

Therapeutic Thresholds of Hydroxychloroquine Blood Levels: Physiologic and Social Determinants of Low Hydroxychloroquine Blood Levels

1:00PM-3:00PM: Abstract Number: 0357

Voclosporin Is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations

1:00PM-3:00PM: Abstract Number: 0368

Which Are the Best Therapeutic Strategies for Systemic Lupus Erythematosus Severe Thrombocytopenia? A Ten Year Analysis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].